Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer.

Journal: Oncotarget
Published Date:

Abstract

PURPOSE: The aim of our retrospective study was to determine the time to progression to castration-resistant prostate cancer (CRPC) in prostate cancer patients who undergo combined androgen blockade (CAB), as well as their prognoses.

Authors

  • Satoshi Tamada
    Department of Urology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan.
  • Taro Iguchi
    Department of Urology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan.
  • Minoru Kato
  • Jumpei Asakawa
    Department of Urology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan.
  • Kazuaki Kita
    Department of Urology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan.
  • Sayaka Yasuda
    Department of Urology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan.
  • Takeshi Yamasaki
    Department of Urology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan.
  • Yudai Matsuoka
    Department of Urology, Bell Land General Hospital, Naka-ku, Sakai City, Osaka 599-8247, Japan.
  • Kazuyuki Yamaguchi
    Department of Urology, Bell Land General Hospital, Naka-ku, Sakai City, Osaka 599-8247, Japan.
  • Kentaro Matsumura
    Department of Urology, Bell Land General Hospital, Naka-ku, Sakai City, Osaka 599-8247, Japan.
  • Ishun Go
    Department of Urology, Bell Land General Hospital, Naka-ku, Sakai City, Osaka 599-8247, Japan.
  • Tetsuji Ohmachi
    Department of Urology, Bell Land General Hospital, Naka-ku, Sakai City, Osaka 599-8247, Japan.
  • Tatsuya Nakatani
    Department of Urology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan.

Keywords

No keywords available for this article.